Brief: ABVC BioPharma Provides Vitargus Update Of Phase II Vitargus Study Protocol Received Thai FDA Approval
17/11/2022 13:41
Nov 17 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA PROVIDES VITARGUS® UPDATE - PHASE II
VITARGUS®
STUDY PROTOCOL RECEIVED THAI FDA APPROVAL
Source text for Eikon: ID:nGNXX1ZrP
Further company coverage: ABVC.O
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma Says Biokey Share Distribution Rescheduled For August 21
NASDAQ RESUMED AT 09:05 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:43 PM
Brief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon